Sms Pharmaceuticals

Hyderabad, India Founded: 1990 • Age: 36 yrs Listed
Active pharmaceutical ingredients and intermediates are manufactured by SMS Pharmaceuticals.
Request Access
Report Incorrect Data
Page last updated

About Sms Pharmaceuticals

Sms Pharmaceuticals is a publicly listed company based in Hyderabad (India) founded in 1990. Active pharmaceutical ingredients and intermediates are manufactured by SMS Pharmaceuticals. The company has 516 employees. Its Indian entity Sms Pharmaceuticals Limited reported revenue of ₹895 Cr. Sms Pharmaceuticals offers products and services including API Manufacturing and Intermediates. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.

Company details

SMS Pharmaceuticals was established in 1990 in Hyderabad, India, initially as a single-product manufacturer in the pharmaceutical sector. APIs and intermediates are produced for various therapeutic segments from multiple locations. Four facilities have received approvals from FDA, PMDA, EUGMP (Germany), KFDA, TGA, and COFEPRIS (Mexico). Contract research services are offered, with products reaching over 70 countries. Process reactions and reactor volumes up to 15KL are managed.

  • Headquarters Hyderabad, India
  • Employees 516
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website smspharma.com
  • Social LinkedIn YouTube
  • Legal Name Sms Pharmaceuticals Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹4,839 Cr

    SMSPHARMA · NSE

  • Share Price
    ₹498.55

    -3.51% today

  • Revenue
    ₹887 Cr

    FY 2025-26 · +13.3% YoY

  • EBITDA
    ₹171 Cr

    Margin 19.3%

  • Net Profit
    ₹102 Cr

    FY 2025-26 · +47.5% YoY

  • P/E (TTM)
    42.1x

    P/B 5.8x

  • ROE
    12.3%

    ROCE 13.3%

  • Debt / Equity
    0.47

    Interest cover 17.7x

  • Employee Count
    516

Products & Services of Sms Pharmaceuticals

Sms Pharmaceuticals offers a comprehensive portfolio of products and services, including API Manufacturing and Intermediates.

API Manufacturing
Production

Manufactures Active Pharmaceutical Ingredients for global markets

Intermediates
Chemical Intermediates

Produces intermediates for pharmaceutical applications

Apps and channels of Sms Pharmaceuticals

its YouTube channel SMS Pharmaceuticals Ltd has 162 subscribers and 1 videos.

SMS Pharmaceuticals Ltd
YouTube 162 subscribers 1 videos Gaming
Open channel

Videos from Sms Pharmaceuticals

The most watched videos on Sms Pharmaceuticals's YouTube channel, SMS Pharmaceuticals Ltd (162 subscribers). Click a video to play it here.

SMS Pharmaceuticals Ltd Ibuprofen Manufacturing Block
11.9K views

More on SMS Pharmaceuticals Ltd.

Board of directors of Sms Pharmaceuticals Limited (Sms Pharmaceuticals)

Sms Pharmaceuticals Limited is the primary company behind Sms Pharmaceuticals. The board of Sms Pharmaceuticals Limited currently have 8 directors; the longest-serving is Ramesh Babu Potluri, appointed in 2008. 21 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ramesh Babu Potluri
DIN 00166381
Managing Director01 Dec 200817 yrs 11 moSms Pharmaceuticals Limited
Shravan Kudaravalli
DIN 06905851
Director26 May 20188 yrs 5 moSms Pharmaceuticals Limited
Srinivas Sarvepalli
DIN 02292051
Director12 Aug 20197 yrs 2 moSms Pharmaceuticals Limited
Vamsi Krishna Potluri
DIN 06956498
Whole-time director05 Jun 20206 yrs 5 moSms Pharmaceuticals Limited
Suresh Kumar Gangavarapu
DIN 00183128
Director12 Aug 20242 yrs 2 moSms Pharmaceuticals Limited
Shanti Sree Bolleni
DIN 07092258
Director12 Aug 20242 yrs 2 moSms Pharmaceuticals Limited
Trilok Potluri
DIN 07634613
Director12 Aug 20242 yrs 2 moSms Pharmaceuticals Limited
Sunkara Venkata Satya Shiva Prasad
DIN 10404277
Director12 Aug 20242 yrs 2 moSms Pharmaceuticals Limited

People of Sms Pharmaceuticals

13 people are tracked at Sms Pharmaceuticals (7 in leadership, 4 in board & advisors, 2 in team); the tracked headcount is 516.

NameRoleGroup
Ramesh Babu Potluri
Chairman & Managing DirectorLeadership
Vamsi Krishna Potluri
Executive DirectorLeadership
Lakshmi Naryana Tammineedi
CFOLeadership
Lakshmi Narayana Tammineedi
Chief Financial OfficerLeadership
Rama Rao
Deputy General Manager- QALeadership
Phani Kumar
Deputy General ManagerLeadership
Dileep Kumar Mamidala
HEAD AR D Sr ManagerLeadership
Sarvepalli Srinivas
DirectorBoard & advisors
T. Neelaveni
DirectorBoard & advisors
P. Sarath Kumar
DirectorBoard & advisors
Shravan Kudaravalli
DirectorBoard & advisors
Thirumalesh Thumma
Company SecretaryTeam
J Ramdevudu
Research And Development ChemistTeam
Premium access

Complete people profiles for Sms Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Sms Pharmaceuticals

Sms Pharmaceuticals is a publicly listed company on the NSE with ticker symbol SMSPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date28 Feb 2007
  • Listed onBSE: 532815 · NSE: SMSPHARMA
  • Listed entitySMS Pharmaceuticals Limited
  • Exchange sectorHealth technology
  • ISININE812G01025
  • Share price₹432.85 (-1.24% on the day) · 2026-10-14
  • Market capitalisation₹4,100 Cr
  • Price to earnings38.4
  • EPS (diluted, trailing year)₹11.27
  • Dividend yield0.09%
  • Volume (last session)92,350

Financials of Sms Pharmaceuticals

Exchange-reported figures of Sms Pharmaceuticals Limited, the listed company behind Sms Pharmaceuticals (NSE: SMSPHARMA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹887 Cr
+13.3% YoY
EBITDA
₹171 Cr
+23.2% YoY
Profit After Tax
₹102 Cr
+47.5% YoY
Net Worth
₹786 Cr
+22.8% YoY
Total Assets
₹1,152 Cr
+21.1% YoY
Total Debt
₹365 Cr
+17.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue887783709522520563412
Revenue growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
EBITDA17113911754.5511512180.03
EBITDA margin+19.3%+17.8%+16.5%+10.5%+22.1%+21.5%+19.4%
Profit before tax11792.3366.115.3668.5091.1250.75
Net profit10269.1249.80(7.01)62.2262.5331.60
Net profit margin+11.5%+8.8%+7.0%-1.3%+12.0%+11.1%+7.7%
EPS (₹)11.157.805.89(0.83)7.357.393.73
Balance sheet
Total assets1,152952818716735667507
Net worth786640536461470411348
Total debt365311281254263255157
Cash & bank46.0741.5936.207.4746.6640.519.65
Net working capital478401361288292218158
Cash flow
Cash from operations59.2281.7150.1222.4545.0690.4539.71
Cash from investing(131)(123)(52.07)(29.76)(27.15)(152)(42.56)
Cash from financing76.0347.0830.68(31.97)(11.75)92.02(2.40)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue316207238210242196248173
Revenue growth (YoY)+30.4%+5.6%-4.1%+21.4%+23.2%+19.2%--
Other income1.341.742.573.751.430.591.422.13
EBITDA67.6640.9539.9043.6548.3739.3740.8133.21
EBITDA margin+21.4%+19.8%+16.8%+20.7%+20.0%+20.1%+16.4%+19.2%
Depreciation10.449.9910.1310.0210.029.758.648.70
Interest5.745.505.286.225.745.845.074.20
Profit before tax52.8227.2027.0631.1634.0424.3728.5222.44
Tax13.257.006.107.978.915.658.445.36
Net profit39.5720.2020.9623.1925.1318.7220.0817.08
EPS (₹)4.262.233.582.592.842.312.402.15
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue887783709522520563412
Revenue growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
EBITDA17114011754.7511512180.03
EBITDA margin+19.3%+17.9%+16.5%+10.5%+22.1%+21.5%+19.4%
Profit before tax11693.3066.335.5668.6591.1250.75
Net profit87.6068.3549.394.1368.0360.9732.71
Net profit margin+9.9%+8.7%+7.0%+0.8%+13.1%+10.8%+7.9%
EPS (₹)9.587.715.840.488.047.203.86
Balance sheet
Total assets1,171985852751759685526
Net worth805673570495494428367
Total debt365311281254263255157
Cash & bank45.9841.5836.207.4746.6640.519.65
Net working capital477401361288292218158
Cash flow
Cash from operations60.6881.7150.1222.4545.0690.4539.71
Cash from investing(132)(123)(52.07)(29.76)(27.15)(152)(42.56)
Cash from financing76.0347.0830.68(31.97)(11.75)92.02(2.40)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue316207238210242196248173
Revenue growth (YoY)+30.4%+5.6%-4.1%+21.4%+23.2%+19.2%--
Other income1.341.742.573.751.430.591.422.13
Total expenses249165198167194157207140
EBITDA67.2441.8939.8843.8048.3838.8641.3533.30
EBITDA margin+21.3%+20.2%+16.8%+20.8%+20.0%+19.8%+16.7%+19.2%
Depreciation10.329.9910.1310.0210.029.758.648.70
Interest5.745.505.286.225.745.845.074.20
Profit before tax52.5228.1427.0431.3134.0523.8629.0622.53
Tax13.397.016.127.978.915.658.445.36

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 06 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue316207238210242196248173
Revenue growth (YoY)+30.4%+5.6%-4.1%+21.4%+23.2%+19.2%--
Other income1.341.742.573.751.430.591.422.13
EBITDA67.6640.9539.9043.6548.3739.3740.8133.21
EBITDA margin+21.4%+19.8%+16.8%+20.7%+20.0%+20.1%+16.4%+19.2%
Depreciation10.449.9910.1310.0210.029.758.648.70
Interest5.745.505.286.225.745.845.074.20
Profit before tax52.8227.2027.0631.1634.0424.3728.5222.44
Tax13.257.006.107.978.915.658.445.36
Net profit39.5720.2020.9623.1925.1318.7220.0817.08
EPS (₹)4.262.233.582.592.842.312.402.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue887783709522520563412
Revenue growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
Other income8.356.224.464.915.203.455.11
Total expenses716644592468405442332
Employee cost0.0080.0864.1550.0851.0241.1739.35
EBITDA17113911754.5511512180.03
EBITDA margin+19.3%+17.8%+16.5%+10.5%+22.1%+21.5%+19.4%
Depreciation39.9234.3431.5232.1332.1522.2822.07
Interest23.0818.5423.6021.9719.1611.1912.32
Profit before tax11792.3366.115.3668.5091.1250.75
Tax28.6424.9416.911.470.6230.1618.07
Net profit10269.1249.80(7.01)62.2262.5331.60
Net profit margin+11.5%+8.8%+7.0%-1.3%+12.0%+11.1%+7.7%
EPS (₹)11.157.805.89(0.83)7.357.393.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.378.878.478.478.478.478.47
Reserves & surplus776615499452462402340
Shareholders' funds (net worth)786640536461470411348
Minority interest0.000.000.000.000.000.000.00
Secured loans364310279289259249151
Unsecured loans1.201.201.79(34.84)4.355.265.98
Total debt365311281254263255157
Total liabilities1,152952818716735667507
Assets
Gross block801760631576571559361
Net block534533437412438457280
Capital work in progress12234.6730.2733.1911.006.7442.12
Investments26.2811.6810.9410.5221.5327.3025.81
Inventories351285234224251138129
Sundry debtors21620323614848.5210648.77
Cash & bank balances46.0741.5936.207.4746.6640.519.65
Loans & advances24.8624.9227.7631.3330.7825.3531.16
Total current assets638554534411377309219
Total current liabilities16015317312384.8391.4161.13
Net working capital478401361288292218158
Total assets1,152952818716735667507
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash41.4036.047.3146.5840.429.5414.80
Net cash from operating activities59.2281.7150.1222.4545.0690.4539.71
Net cash from investing activities(131)(123)(52.07)(29.76)(27.15)(152)(42.56)
Net cash from financing activities76.0347.0830.68(31.97)(11.75)92.02(2.40)
Net change in cash4.485.3628.73(39.28)6.1630.88(5.25)
Closing cash46.0741.5936.207.4746.6640.519.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
EBITDA growth+23.2%+19.0%+114.1%-52.4%-5.4%+51.4%-
PBT growth+26.3%+39.7%+1133.4%-92.2%-24.8%+79.6%-18.6%
Net income growth+47.5%+38.8%+810.4%-111.3%-0.5%+97.9%-
Revenue CAGR (3Y)+19.3%+14.6%+8.0%+8.2%+3.8%+6.8%-2.0%
EBITDA CAGR (3Y)+46.5%+6.6%-1.2%-12.0%+8.3%+9.1%+2.1%
Profitability & leverage
Net income margin+9.9%+8.6%+6.9%+0.8%+13.1%+10.8%+7.9%
Return on capital employed+13.3%+12.5%+11.7%+3.8%+12.5%+17.4%+13.0%
Return on net worth+12.4%+11.5%+9.9%+0.8%+15.4%+16.1%+9.8%
Debt / equity0.470.500.540.560.590.540.45
Long-term debt / equity0.220.220.280.330.340.290.20
Interest cover17.7317.7227.6897.9923.2411.3221.26
Efficiency & per share
Fixed asset turnover1.241.201.250.970.981.331.29
Inventory turnover3.063.223.292.342.864.583.41
Debtors turnover4.643.803.915.637.207.9212.12
EPS (₹)10.897.805.89(0.83)7.357.393.73
Dividend per share (₹)0.400.400.400.300.300.300.25
Book value per share (₹)83.9170.3659.9854.4055.5648.5041.14
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue316207238210242196248173
Revenue growth (YoY)+30.4%+5.6%-4.1%+21.4%+23.2%+19.2%--
Other income1.341.742.573.751.430.591.422.13
Total expenses249165198167194157207140
EBITDA67.2441.8939.8843.8048.3838.8641.3533.30
EBITDA margin+21.3%+20.2%+16.8%+20.8%+20.0%+19.8%+16.7%+19.2%
Depreciation10.329.9910.1310.0210.029.758.648.70
Interest5.745.505.286.225.745.845.074.20
Profit before tax52.5228.1427.0431.3134.0523.8629.0622.53
Tax13.397.016.127.978.915.658.445.36
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue887783709522520563412
Revenue growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
Other income8.356.224.464.915.203.455.11
Total expenses716643592467405442332
Employee cost0.0069.7256.7850.0851.0241.1739.35
EBITDA17114011754.7511512180.03
EBITDA margin+19.3%+17.9%+16.5%+10.5%+22.1%+21.5%+19.4%
Depreciation39.9234.3431.5232.1332.1522.2822.07
Interest23.0818.5423.6021.9719.1611.1912.32
Profit before tax11693.3066.335.5668.6591.1250.75
Tax28.6624.9416.911.470.6230.1618.07
Net profit87.6068.3549.394.1368.0360.9732.71
Net profit margin+9.9%+8.7%+7.0%+0.8%+13.1%+10.8%+7.9%
EPS (₹)9.587.715.840.488.047.203.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.378.878.478.478.478.478.47
Reserves & surplus795648533487485420359
Shareholders' funds (net worth)805673570495494428367
Secured loans364310279289259249151
Unsecured loans1.201.201.79(34.84)4.355.265.98
Total debt365311281254263255157
Total liabilities1,171985852751759685526
Assets
Gross block801760631576571559361
Net block534533437412438457280
Capital work in progress11634.6730.2733.1911.006.7442.12
Investments52.1145.1145.1045.1045.0045.0045.00
Inventories351285234224251138129
Sundry debtors21620323614848.5210648.77
Cash & bank balances45.9841.5836.207.4746.6640.519.65
Loans & advances23.7524.9227.7631.3330.7825.3531.16
Total current assets637554534411377309219
Total current liabilities15915317312384.8391.4161.13
Net working capital477401361288292218158
Total assets1,171985852751759685526
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash41.3936.047.3146.5840.429.5414.80
Net cash from operating activities60.6881.7150.1222.4545.0690.4539.71
Net cash from investing activities(132)(123)(52.07)(29.76)(27.15)(152)(42.56)
Net cash from financing activities76.0347.0830.68(31.97)(11.75)92.02(2.40)
Net change in cash4.395.3528.73(39.28)6.1630.88(5.25)
Closing cash45.9841.5836.207.4746.6640.519.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.3%+10.4%+35.9%+0.4%-7.7%+36.7%-
EBITDA growth+22.1%+19.6%+113.7%-52.3%-5.3%+51.4%-
PBT growth+24.6%+40.7%+1093.0%-91.9%-24.7%+79.6%-18.6%
Net income growth+28.2%+38.4%+1095.9%-93.9%+11.6%+86.4%-
Revenue CAGR (3Y)+19.3%+14.6%+8.0%+8.2%+3.8%+6.8%-2.0%
EBITDA CAGR (3Y)+46.2%+6.8%-1.2%-11.9%+8.4%+9.1%+2.1%
Profitability & leverage
Net income margin+9.9%+8.7%+7.0%+0.8%+13.1%+10.8%+7.9%
Return on capital employed+13.0%+12.2%+11.2%+3.7%+12.2%+16.9%+12.5%
Return on net worth+11.9%+11.0%+9.3%+0.8%+14.8%+15.3%+9.2%
Debt / equity0.460.480.500.520.560.520.43
Long-term debt / equity0.210.210.260.310.330.280.19
Interest cover17.7817.5527.6197.1323.1911.3221.26
Efficiency & per share
Fixed asset turnover1.241.201.250.970.981.331.29
Inventory turnover3.063.223.292.342.864.583.41
Debtors turnover4.643.803.915.637.207.9212.12
EPS (₹)9.357.715.840.488.047.203.86
Dividend per share (₹)0.400.400.400.300.300.300.25
Book value per share (₹)85.9374.1364.0258.4958.3350.5943.40

Similar companies to Sms Pharmaceuticals

Sms Pharmaceuticals has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Laurus Labs
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
Symbiotec
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
SeQuent
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed similar companies of Sms Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Sms Pharmaceuticals

The website of Sms Pharmaceuticals (smspharma.com) receives about 3K visits a month and ranks #2,783,668 among all websites worldwide, #3,748 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3K

    ▼ 76.4% vs previous month

  • Unique visitors
    1.9K

    per month

  • Global rank
    #2,783,668

    among all websites

  • Category rank
    #3,748

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Sms Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Ajanta Pharma
ajantapharma.com
100%
20.1K#1,412,069View details
Natco Pharma
natcopharma.co.in
98%
19.8K#1,133,324View details
Alembic Pharmaceuticals
alembicpharmaceuticals.com
95%
23K#2,083,600View details
Cadila Pharmaceuticals Limited
cadilapharma.com
91%
18.5K#1,452,788View details
Akorn
akorn.com
88%
#11,843,991View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 20 similar websites and full traffic analytics for Sms Pharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 20 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Sms Pharmaceuticals (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sms Pharmaceuticals

SMSPHARMA: Q2 SL NET PROFIT 391M RUPEES VS 251M (YOY); Q2 REVENUE 3.2B RUPEES VS 2.4B (YOY)
Exchange Update • 3 days ago
SMSPHARMA: Q2 EBITDA 672M RUPEES VS 484M (YOY); Q2 EBITDA MARGIN 21.3% VS 19.96% (YOY)
Exchange Update • 3 days ago
Sigachi Industries Ltd leads losers in 'B' group | Capital Market News - Business Standard
Business Standard • 1 month ago
SMS Pharmaceuticals March-Quarter Consol Net Profit 327.1 Million Rupees
Reuters • 5 months ago
Sms Pharmaceuticals Says Tax Demand Reduced To 4 Million Rupees From 71.9 Million Rupees
Reuters • 6 months ago
SMS Pharmaceuticals Clears USFDA Inspection at Vizag API Facility With One Observation | India Infoline
India Infoline • 10 months ago
SMS Pharmaceuticals Says Completion Of USFDA Inspection At Vizag Manufacturing Facility
Reuters • 11 months ago
SMS Pharmaceuticals clears USFDA inspection at Vizag API plant with one minor observation - CNBC TV18
CNBCTV18 • 11 months ago
India's SMS Pharma gains after unit gets US drug regulator approval for Ranitidine
Reuters • 11 months ago
SMS Pharmaceuticals Says VKT Pharma Receives US FDA Approval For Reformulated Ranitidine
Reuters • 11 months ago
Premium access

Complete news archive for Sms Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sms Pharmaceuticals

Sms Pharmaceuticals was founded in 1990.

Sms Pharmaceuticals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Sms Pharmaceuticals has 516 employees.

The primary company behind Sms Pharmaceuticals, Sms Pharmaceuticals Limited, reported revenue of ₹895 Cr for FY 2026, up 13% year on year.

SMS Pharmaceuticals was established in 1990 in Hyderabad, India, initially as a single-product manufacturer in the pharmaceutical sector. APIs and intermediates are produced for various therapeutic segments from multiple locations. Four facilities have received approvals from FDA, PMDA, EUGMP (Germany), KFDA, TGA, and COFEPRIS (Mexico). Contract research services are offered, with products reaching over 70 countries. Process reactions and reactor volumes up to 15KL are managed.

Sms Pharmaceuticals's top competitors include Laurus Labs, Symbiotec and SeQuent.

Sms Pharmaceuticals offers API Manufacturing and Intermediates.

Yes, Sms Pharmaceuticals is publicly traded on NSE under the ticker symbol SMSPHARMA.

Sms Pharmaceuticals operates through Sms Pharmaceuticals Limited.

The legal entities of Sms Pharmaceuticals currently have 10 directors, including Shravan Kudaravalli, Srinivas Sarvepalli, Ramesh Babu Potluri and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available